{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-040848","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.839522+00:00","generated_at":"2026-06-17T07:12:41.154024+00:00","sec_items":["1.01","1.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Liquidia and GSK restructure PRINT license; Liquidia gains rights for most inhaled uses","bullets":["New non-exclusive, royalty-free license replaces 2012 collaboration; GSK gets pre-clinical research rights only.","Liquidia may apply PRINT to all inhaled formulations except certain GSK proprietary molecules.","GSK must seek expanded license for clinical/commercial use; Liquidia retains ownership of its technology.","Agreement effective March 31, 2023; press released April 3, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-040848","json":"https://secwatch.observer/filing/0001104659-23-040848.json","markdown":"https://secwatch.observer/filing/0001104659-23-040848.md","text":"https://secwatch.observer/filing/0001104659-23-040848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/tm2311372d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:12:41.154024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f07904885c38f4c8a0ce2dfe9851c527bad4b49","claim":"Liquidia Corp entered into Research License Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).","evidence_excerpt":"On March 31, 2023, Liquidia Corporation, a Delaware corporation (the “Company”) through Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and wholly owned subsidiary of the Company, entered into a Research License Agreement (the “Agreement”) with Glaxo Group Limited, a company organized and existing under the laws of England (“GSK”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Glaxo Group Limited (GSK)"},{"label":"Effective","value":"2023-03-31"}],"fact_type":"material_agreement"},{"claim_id":"530b8e36018ac43719c02df81c18b3745c5f7a7c","claim":"Liquidia Corp terminated Inhalation Collaboration and Option Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).","evidence_excerpt":"The Agreement supersedes and replaces that certain Inhalation Collaboration and Option Agreement, dated as of June 15, 2012, by and between Liquidia Technologies and GSK, as amended on May 13, 2015, November 19, 2015 and June 24, 2019 (the “Prior Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Glaxo Group Limited (GSK)"},{"label":"Effective","value":"2023-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}